These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23892220)

  • 41. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Testosterone in prostate cancer: the Bethesda consensus.
    Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
    BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
    Kennealey GT; Furr BJ
    Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    Molina A; Belldegrun A
    J Urol; 2011 Mar; 185(3):787-94. PubMed ID: 21239012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
    J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estradiol for the mitigation of adverse effects of androgen deprivation therapy.
    Russell N; Cheung A; Grossmann M
    Endocr Relat Cancer; 2017 Aug; 24(8):R297-R313. PubMed ID: 28667081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical and laboratoristic strategy in late onset hypogonadism.
    Lombardo F; Lupini C; Meola A; Pallotti F; Gandini L; Lenzi A
    Acta Biomed; 2010; 81 Suppl 1():85-8. PubMed ID: 20518196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
    Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies - a mini-review.
    Mäkinen JI; Huhtaniemi I
    Gerontology; 2011; 57(3):193-202. PubMed ID: 20689266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sexual adjustment to androgen deprivation therapy: struggles and strategies.
    Walker LM; Robinson JW
    Qual Health Res; 2012 Apr; 22(4):452-65. PubMed ID: 21911504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypogonadism and erectile dysfunction: an overview.
    Gurbuz N; Mammadov E; Usta MF
    Asian J Androl; 2008 Jan; 10(1):36-43. PubMed ID: 18087642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen-deprivation therapy and pancreatic β-cell dysfunction in men.
    Mauvais-Jarvis F
    J Diabetes Complications; 2016 Apr; 30(3):389-90. PubMed ID: 26861947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.